Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Aon appoints Andy Marcell to serve as CEO of Global Solutions
DUBLIN, June 2, 2025 /PRNewswire/ --Â Aon plc (NYSE: AON), a leading global…
Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or…
AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help Global Pharma Manage Supplier Site Risk
FRANKFURT, Germany, May 29, 2025 /PRNewswire/ -- Qualifyze, already the global leader…